CTOs on the Move


 
The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.vocare.com
  • 8888, Keystone Crossing
    Indianapolis, IN USA 46240
  • Phone: 317.658.0005

Executives

Name Title Contact Details

Similar Companies

Pacific Biomarkers

Pacific Biomarkers is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tapimmune Inc

Tapimmune Inc is a Issaquah, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vivera Pharmaceuticals

Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH®, a smart dose-controlled medical device. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

Castle Hill Technologies

Castle Hill Technologies is a Attleboro Falls, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.